QUICK ANSWER · AEO / GEO
An experimental small-molecule NNMT inhibitor, not a peptide, with predominantly preclinical evidence.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- whether any formulation is tolerable or effective in humans
- validated human pharmacokinetics and target engagement
- which tissues are affected and whether NNMT inhibition has harmful context-dependent effects
- long-term metabolic, hepatic, cardiovascular, neurologic and oncologic consequences
- drug interactions and risks in pregnancy, lactation or chronic disease
- comparability of 5-Amino-1MQ free molecule, iodide and marketed products
- current Thailand, EU and UK product-specific regulatory status pending direct verification
What limits these conclusions?
- There is no verified human evidence base to grade for efficacy or safety. Published findings come from cells and small animal studies with model-specific diets, routes, exposure periods and endpoints. Some papers study genetic NNMT knockdown or different inhibitors rather than 5-Amino-1MQ itself. Apparent absence of adverse effects in short mouse experiments cannot establish human safety.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.accessdata.fda.gov/scripts/cder/daf/
- https://precision.fda.gov/ginas/app/ui/substances/6f07ddfc-fdef-4319-b81f-3614668ce23c
- https://precision.fda.gov/ginas/app/ui/substances/244e5c81-594e-4721-b7cd-6dfdf4f068e0
- https://precision.fda.gov/ginas/app/ui/substances/1c10afd2-877c-4d7b-9161-46767b643b17
- https://clinicaltrials.gov/search?term=%225-Amino-1MQ%22
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026
- https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
- https://pubmed.ncbi.nlm.nih.gov/29155147/
- https://pubmed.ncbi.nlm.nih.gov/39161060/
- https://pubmed.ncbi.nlm.nih.gov/35013352/
- https://pubmed.ncbi.nlm.nih.gov/33645410/
- https://pubmed.ncbi.nlm.nih.gov/24717514/
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is 5-Amino-1MQ?
5-Amino-1MQ is described pharmacologically as Experimental small-molecule nicotinamide N-methyltransferase inhibitor; not a peptide. An experimental small-molecule NNMT inhibitor, not a peptide, with predominantly preclinical evidence.
Does 5-Amino-1MQ have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is 5-Amino-1MQ approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.